Journal
MOLECULAR CANCER THERAPEUTICS
Volume 20, Issue 4, Pages 726-738Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-20-0505
Keywords
-
Categories
Funding
- Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research
- Sloan Foundation
- Siebel Foundation
- NIH [5R01CA218500, 1R01GM120272]
- Microscopy-Nanoscale Pilot Grant from Harvard Catalyst [R01-CA160979]
- BCRF-AACR
- Brent Leahey Fund
Ask authors/readers for more resources
The oncogenic transcription factor STAT3 is aberrantly activated in breast cancers, leading to changes in cellular lipid distribution. By using layer-by-layer nanoparticles with different surface layers, targeted therapy can be achieved for STAT3-activated breast cancer cells, showing promising therapeutic effects.
The oncogenic transcription factor STAT3 is aberrantly activated in 70% of breast cancers, including nearly all triple-negative breast cancers (TNBCs). Because STAT3 is difficult to target directly, we considered whether metabolic changes driven by activated STAT3 could provide a therapeutic opportunity. We found that STAT3 prominently modulated several lipid classes, with most profound effects on N-acyl taurine and arachidonic acid, both of which are involved in plasma membrane remodeling. To exploit these metabolic changes therapeutically, we screened a library of layer-bylayer (LbL) nanoparticles (NPs) differing in the surface layer that modulates interactivity with the cell membrane. We found that poly-L-glutamic acid (PLE)-coated NPs bind to STAT3-transformed breast cancer cells with 50% greater efficiency than to nontransformed cells, and the heightened PLE-NP binding to TNBC cells was attenuated by STAT3 inhibition. This effect was also observed in densely packed three-dimensional breast cancer organoids. As STAT3-transformed cells show greater resistance to cytotoxic agents, we evaluated whether enhanced targeted delivery via PLE-NPs would provide a therapeutic advantage. We found that cisplatin-loaded PLE-NPs induced apoptosis of STAT3-driven cells at lower doses compared with both unencapsulated cisplatin and cisplatin-loaded nontargeted NPs. In addition, because radiation is commonly used in breast cancer treatment, and may alter cellular lipid distribution, we analyzed its effect on PLE-NP-cell binding. Irradiation of cells enhanced the STAT3-targeting properties of PLE-NPs in a dose-dependent manner, suggesting potential synergies between these therapeutic modalities. These findings suggest that cellular lipid changes driven by activated STAT3 may be exploited therapeutically using unique LbL NPs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available